Literature DB >> 27875000

Combined hepatocellular-cholangiocarcinoma: Gadoxetic acid-enhanced MRI findings correlated with pathologic features and prognosis.

So Hyun Park1, Seung Soo Lee1, Eunsil Yu2, Hyo Jeong Kang2,3, Yangsoon Park2, So Yeon Kim1, So Jung Lee1, Yong Moon Shin1, Moon Gyu Lee1.   

Abstract

PURPOSE: To evaluate gadoxetic acid-enhanced magnetic resonance imaging (MRI) findings of combined hepatocellular cholangiocarcinoma (cHCC-CC) with special emphasis on correlation of MRI findings with histopathologic tumor characteristics and survival outcomes after curative surgery.
MATERIALS AND METHODS: Our Institutional Review Board approved this study, with a waiver of informed consent. For 82 patients (64 men, 18 women; mean age, 54.0 years; age range, 30-81) with surgically confirmed cHCC-CCs, we evaluated clinical features, histologic findings, and tumor morphologic and enhancement features on gadoxetic acid-enhanced liver MRI at 1.5T (n = 67) or 3.0T (n = 15). Imaging features of cHCC-CCs were correlated with pathologic findings according to the 2010 World Health Organization classification system. Tumors were categorized as hypervascular or nonhypervascular based on arterial phase enhancement and were compared with respect to overall and recurrence-free survival after curative-intent surgery.
RESULTS: Of the 82 lesions, 48 showing global arterial phase enhancement were categorized as the hypervascular group, while 34 lesions demonstrating rim, peripheral, or isoenhancement were categorized as the nonhypervascular group. There was no significant difference in MRI findings between pathologic tumor types (classical type versus stem cell feature type, P = 0.324-1.0). Compared with the nonhypervascular group, the hypervascular group had a larger HCC component (P = 0.014), smaller CC component (P = 0.001), and lesser amount of fibrotic stroma (P = 0.006) on pathologic analysis and was an independent factor associated with better overall survival after surgical resection (P = 0.033).
CONCLUSION: Gadoxetic acid-enhanced MRI findings of cHCC-CCs were diverse, reflecting heterogeneous histologic features. The hypervascular group on MRI is associated with a larger HCC component, smaller CC component, less fibrotic stroma, and better overall survival after curative surgery than the nonhypervascular group. LEVEL OF EVIDENCE: 4 J. MAGN. RESON. IMAGING 2017;46:267-280.
© 2016 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  2010 WHO classification; combined hepatocellular-cholangiocarcinoma; gadoxetic acid-enhanced MRI

Mesh:

Substances:

Year:  2016        PMID: 27875000     DOI: 10.1002/jmri.25568

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  14 in total

1.  Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging.

Authors:  Sun Kyung Jeon; Ijin Joo; Dong Ho Lee; Sang Min Lee; Hyo-Jin Kang; Kyoung-Bun Lee; Jeong Min Lee
Journal:  Eur Radiol       Date:  2018-06-28       Impact factor: 5.315

2.  How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?

Authors:  Hong Seon Lee; Myeong-Jin Kim; Chansik An
Journal:  Eur Radiol       Date:  2018-12-14       Impact factor: 5.315

3.  Gadoxetic acid-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: can hypointensity on the late portal venous phase be used as an alternative to washout?

Authors:  Kyoung A Baek; Seung Soo Kim; Hyeong Cheol Shin; Jeong Ah Hwang; Seo-Youn Choi; Woong Hee Lee; Chan Ho Park; Hyoung Nam Lee; Nam Hun Heo
Journal:  Abdom Radiol (NY)       Date:  2020-09

4.  Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors.

Authors:  Tyler J Fraum; Roberto Cannella; Daniel R Ludwig; Richard Tsai; Muhammad Naeem; Maverick LeBlanc; Amber Salter; Allan Tsung; Anup S Shetty; Amir A Borhani; Alessandro Furlan; Kathryn J Fowler
Journal:  Eur Radiol       Date:  2019-10-25       Impact factor: 5.315

5.  Diagnostic performance of the LR-M criteria and spectrum of LI-RADS imaging features among primary hepatic carcinomas.

Authors:  Seung-Seob Kim; Sunyoung Lee; Jin-Young Choi; Joon Seok Lim; Mi-Suk Park; Myeong-Jin Kim
Journal:  Abdom Radiol (NY)       Date:  2020-11

Review 6.  Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.

Authors:  Mina Komuta
Journal:  Clin Mol Hepatol       Date:  2022-01-14

7.  The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection.

Authors:  Seong Kyun Na; Gwang Hyeon Choi; Han Chu Lee; Yong Moon Shin; Jihyun An; Danbi Lee; Ju Hyun Shim; Kang Mo Kim; Young-Suk Lim; Young-Hwa Chung; Yung Sang Lee
Journal:  PLoS One       Date:  2018-06-07       Impact factor: 3.240

Review 8.  Combined Hepatocellular-Cholangiocarcinoma: Changes in the 2019 World Health Organization Histological Classification System and Potential Impact on Imaging-Based Diagnosis.

Authors:  Tae Hyung Kim; Haeryoung Kim; Ijin Joo; Jeong Min Lee
Journal:  Korean J Radiol       Date:  2020-07-27       Impact factor: 3.500

9.  Metal implants influence CT scan parameters leading to increased local radiation exposure: A proposal for correction techniques.

Authors:  Ok Kyu Song; Yong Eun Chung; Nieun Seo; Song-Ee Baek; Jin-Young Choi; Mi-Suk Park; Myeong-Jin Kim
Journal:  PLoS One       Date:  2019-08-23       Impact factor: 3.240

Review 10.  Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers.

Authors:  Yeun-Yoon Kim; Mi-Suk Park; Khalid Suliman Aljoqiman; Jin-Young Choi; Myeong-Jin Kim
Journal:  Clin Mol Hepatol       Date:  2019-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.